Characterization of a Potent Neurogenic Compound
Characterization of a Potent Neurogenic Compound
批准号:
8374346
负责人:
DAVID R SCHUBERT
金额:
$28.8万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-01 至 2014-06-30
关键词:
AdultAgeAlzheimer&aposs DiseaseAnimalsAstrocytesBehavioralBiological AssayBrainBrain-Derived Neurotrophic FactorBromodeoxyuridineCell Culture TechniquesCell Differentiation processCell LineCell ProliferationCell divisionCellsCommitDataData SetDevelopmentDominant-Negative MutationFluoxetineGlial Fibrillary Acidic ProteinGoalsHealthHippocampus (Brain)Impaired cognitionIn VitroInvestigationLabelLaboratory StudyLeadLearningLifeMemoryMemory impairmentMethodsModelingMolecularMolecular GeneticsMusNerveNerve DegenerationNeuraxisNeurodegenerative DisordersNeurogliaNeuronsNeuroprotective AgentsNeurotrophic Tyrosine Kinase Receptor Type 2OligodendrogliaPathologyPathway interactionsPharmaceutical PreparationsPhenotypePhysiologic pulsePlayPremature aging syndromeProcessProductionPropertyProteinsProteomicsRadiationRattusRodentRoleSchemeScreening procedureSerotoninServicesSignal PathwayStaining methodStainsStem cellsSubfamily lentivirinaeSynapsesTechnologyTestingTherapeuticTimeTransgenic MiceTransgenic OrganismsWestern BlottingWorkadult neurogenesisage relatedagedbasecell typecognitive functiondrug candidatedrug discoveryhuman embryonic stem cellimmunocytochemistryimprovedin vivomolecular markernerve stem cellnestin proteinneural precursor cellneurogenesisnovelprecursor cellpreventresearch studyresponsesenescencestem cell divisiontherapeutic targetuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Although neurogenesis occurs primarily during development, it is an active process that persists throughout life, and may play a role in normal learning and memory. Decreased levels of neurogenesis occur with age and perhaps in neurodegenerative conditions such as Alzheimer's disease (AD). Therefore, understanding the molecular basis of stem cell division and differentiation within the central nervous system (CNS) deserves thorough investigation. A novel drug discovery paradigm was used to select drug candidates for the treatment of neurodegenerative diseases that is based on efficacy in cell culture models of multiple, age-associated pathologies. This scheme has identified a potent, orally active compound, J147, which facilitates memory in normal rodents, prevents behavioral deficits and synaptic protein loss in AD transgenic mice, and reverses cognitive loss in aged transgenic AD mice. J147 is also neurogenic in mice, in adult rat hippocampal precursor cells in culture, and for human ESC-derived neural precursor cells. In addition, it has the unique ability of inhibiting the division of cells destined to be astrocytes. The overall aim in this study is to identify the type and fate of cells that respond to J147 in the mouse brain and to use this compound to better understand the molecular pathways involved in neurogenesis both in vivo and in cell culture models. Therefore the phenotype of the nerve-like cells made in response to J147 will be characterized both in animals and in a rat hippocampal precursor cell line that can produce either nerve or glia. Because the therapeutic potential of compounds like J147 in AD, it will be asked if J147 can induce neurogenesis in very old mice where other neurogenic compounds fail to act. Importantly, neurogenesis will be reduced by two independent methods and it will be asked if J147 is still able to enhance memory. Finally, a new proteomics approach will be used to identify the molecular signaling pathways responsible for J147-induced cell division and nerve differentiation. Results from this study may lead to a therapeutic application of J147 based upon manipulating neural stem cells to improve CNS health.
PUBLIC HEALTH RELEVANCE: It is now generally recognized that new nerve cells continue to be produced in the adult brain, but there are currently very few ways to stimulate that process. We have recently made a very potent compound that can stimulate the production of new neurons in both young and old mice. The goal of this project is to better characterize the types of nerve cells that this compound generates and determine how it works.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterization of a Potent Neurogenic Compound
-
批准号:8461542
-
项目类别:
-
资助金额:$23.16万
-
财政年份:2012
-
负责人:DAVID R SCHUBERT
-
依托单位:
Pan-Lipoxygenase Inhibitors for CNS Disease
-
批准号:8680099
-
项目类别:
-
资助金额:$37.54万
-
财政年份:2010
-
负责人:DAVID R SCHUBERT
-
依托单位:
Pan-Lipoxygenase Inhibitors for CNS Disease
-
批准号:8290360
-
项目类别:
-
资助金额:$37.54万
-
财政年份:2010
-
负责人:DAVID R SCHUBERT
-
依托单位:
Pan-Lipoxygenase Inhibitors for CNS Disease
-
批准号:8490268
-
项目类别:
-
资助金额:$35.47万
-
财政年份:2010
-
负责人:DAVID R SCHUBERT
-
依托单位:
Pan-Lipoxygenase Inhibitors for CNS Disease
-
批准号:7986374
-
项目类别:
-
资助金额:$39.05万
-
财政年份:2010
-
负责人:DAVID R SCHUBERT
-
依托单位:
Pan-Lipoxygenase Inhibitors for CNS Disease
-
批准号:8084158
-
项目类别:
-
资助金额:$37.54万
-
财政年份:2010
-
负责人:DAVID R SCHUBERT
-
依托单位:
A Novel Family of Neuroprotective Compounds for Stroke
-
批准号:7928155
-
项目类别:
-
资助金额:$81.97万
-
财政年份:2009
-
负责人:DAVID R SCHUBERT
-
依托单位:
A Novel Family of Neuroprotective Compounds for Stroke
-
批准号:7655854
-
项目类别:
-
资助金额:$81.73万
-
财政年份:2009
-
负责人:DAVID R SCHUBERT
-
依托单位:
In Vivo Efficacy of New Neuroprotective Drugs
-
批准号:7847466
-
项目类别:
-
资助金额:$23.44万
-
财政年份:2009
-
负责人:DAVID R SCHUBERT
-
依托单位:
Development and Testing of a Novel Neuroprotective Drug
-
批准号:7140561
-
项目类别:
-
资助金额:$21.43万
-
财政年份:2005
-
负责人:DAVID R SCHUBERT
-
依托单位:
Regulation of APP Degradation and ABeta Secretion
-
批准号:7271875
-
项目类别:
-
资助金额:$41.62万
-
财政年份:2005
-
负责人:DAVID R SCHUBERT
-
依托单位:
Development and Testing of a Novel Neuroprotective Drug
-
批准号:6989828
-
项目类别:
-
资助金额:$21.95万
-
财政年份:2005
-
负责人:DAVID R SCHUBERT
-
依托单位:
Regulation of APP Degradation and ABeta Secretion
-
批准号:7456505
-
项目类别:
-
资助金额:$41.62万
-
财政年份:2005
-
负责人:DAVID R SCHUBERT
-
依托单位:
Regulation of APP Degradation and ABeta Secretion
-
批准号:7069142
-
项目类别:
-
资助金额:$42.86万
-
财政年份:2005
-
负责人:DAVID R SCHUBERT
-
依托单位:
Regulation of APP Degradation and ABeta Secretion
-
批准号:6989556
-
项目类别:
-
资助金额:$43.89万
-
财政年份:2005
-
负责人:DAVID R SCHUBERT
-
依托单位:
Regulation of APP Degradation and ABeta Secretion
-
批准号:7656003
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2005
-
负责人:DAVID R SCHUBERT
-
依托单位:
Redox Sensitive Proteins in Aging and Neurodegeneration
-
批准号:7117309
-
项目类别:
-
资助金额:$37.43万
-
财政年份:2004
-
负责人:DAVID R SCHUBERT
-
依托单位:
Redox Sensitive Proteins in Aging and Neurodegeneration
-
批准号:6862388
-
项目类别:
-
资助金额:$40.49万
-
财政年份:2004
-
负责人:DAVID R SCHUBERT
-
依托单位:
Redox Sensitive Proteins in Aging and Neurodegeneration
-
批准号:6952653
-
项目类别:
-
资助金额:$38.33万
-
财政年份:2004
-
负责人:DAVID R SCHUBERT
-
依托单位:
PHYSIOLOGICAL FUNCTION OF ENDOGENOUS HYDROGEN SULFIDE
-
批准号:6017127
-
项目类别:
-
资助金额:$13.1万
-
财政年份:1998
-
负责人:DAVID R SCHUBERT
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: